insights_auto
Hvorfor har GNMSF gått ned? 2,39%?
GÃ¥ mer i dybdenchevron_right
GNMSF:OTCMKTS
Genmab
367,00Â USD
arrow_downward
−2,39%(−9,00) 1 D
9. okt., 16:00:00 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for GNMSF …
Ã…pne
367,00Â USD
Høy
367,00Â USD
Lav
367,00Â USD
Markedsverdi
22,65Â mrd.
Snittvolum
1,37k
Volum
52,00
52 u høy
396,97Â USD
52Â u lav
232,50Â USD
Beta
0,73
Utestående aksjer
62,41Â mill.
Antall ansatte
3k
Ã…pne
367,00Â USD
Høy
367,00Â USD
Lav
367,00Â USD
Markedsverdi
22,65Â mrd.
Snittvolum
1,37k
Volum
52,00
52 u høy
396,97Â USD
52Â u lav
232,50Â USD
Beta
0,73
Utestående aksjer
62,41Â mill.
Antall ansatte
3k
Nyhetssaker
Fra nettkilder og nyhetspartnere
The Globe and Mail
·
for 17 timer siden
Genmab (GMAB) Receives a Buy from Truist Financial
Investing.com
·
for 3 døgn siden
H.C. Wainwright raises Genmab stock price target on positive trial data
Profil
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US. Wikipedia
Om Genmab
Administrerende direktørJan G. J. van de Winkel
Ansatte3,12k
Grunnlagt11. juni 1998
Hovedkontor-
Sektor-
Nettstedgenmab.com